Company

Drug

Trial Acronym

Phase

Abstract No.

Abstract Title

Non-small Cell Lung Cancer

RYBREVANT (amivantamab) + LECLAZA (lazertinib)

MARIPOSA

III

LBA10

Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

RYBREVANT (amivantamab) + chemotherapy

MARIPOSA-2

III

LBA11

Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis

ALECENSA (alectinib)

ALINA

III

LBA1

Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK+ non-small cell lung cancer (NSCLC): A sub analysis of ALINA

Dato-DXd (datopotamab deruxtecan) 

TROPION-Lung01

III

509MO

Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized Phase III study TROPION-Lung01

Gastrointestinal Tumors

IMFINZI (durvalumab) + FLOT (5-fluorouracil, leucovorin, oxaliplatin and docetaxel)

MATTERHORN

III

129O

Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, Phase III MATTERHORN study

KEYTRUDA (pembrolizumab) + HERCEPTIN (trastuzumab) and chemotherapy

KEYNOTE-811

III

130O

The Phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

LUMAKRAS (sotorasib) + VECTIBIX (panitumumab)

CodeBreak 300

III

91MO

Sotorasib plus panitumumab versus standard-of-care for chemo refractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 Phase III study

Gynecological Cancers

TIVDAK (tisotumab vedotin)

InnovaTV 301

III

288MO

InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, Phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer

Solid Tumors

Trastuzumab deruxtecan (T-DXd)

DESTINY-PanTumor02

II

74MO

Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: Primary analysis from the DESTINY-PanTumor02 (DP-02) study

Milademetan

MANTRA

III

76MO

Efficacy and safety findings from MANTRA: A global, randomized, multicenter, Phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas

Genitourinary Tumors

NUBEQA (darolutamide) + androgen-deprivation therapy (ADT) and docetaxel (DOC)

ARASENS

III

255O

Darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the Phase III ARASENS study

Breast Cancer

TRODELVY (sacituzumab govitecan)

EVER-002

III

LBA4

Sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in Asian patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) metastatic breast cancer (mBC): Results from the Phase III EVER-002 study

TRUQAP (capivasertib) + FASLODEX (fulvestrant)

CAPItello-291

III

LBA5

Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort

KEYTRUDA (pembrolizumab)

KEYNOTE-522

III

LBA3

Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis

Hematological Malignancies

IM19 CAR-T cells

-

Ib/II

328MO

The pivotal clinical study of IM19 CAR-T cells in the treatment of relapsed or refractory aggressive B cell non-Hodgkin lymphomas